Yaoxue Xuebao

Submission On

( Vol 60 , Issue 04 ) |

15 Sep 2025
Day
Hour
Min
Sec
Publish On

( Vol 60 , Issue 03 ) |

31 Aug 2025
Scopus Indexed (2025) scopus
ABCD Indexed (2025) scopus
scopus

Yaoxue Xuebao

Yaoxue Xuebao (ISSN:0513-4870) is a monthly peer-reviewed scopus-indexed journal from 1960, from 1962 to 1966, from 1979 to Present. The publisher of this journal is Chinese Pharmaceutical Association. Yaoxue Xuebao committed to gathering and disseminating excellent research achievements. The journal welcomes all kind of research/review/abstract papers regarding Pharmacology, Toxicology and Pharmaceutics, General Pharmacology and Toxicology and Pharmaceutics Biochemistry, Genetics and Molecular Biology and Molecular Medicine and so on.

Aim And Scope

Yaoxue Xuebao

Pharmacology

Toxicology and Pharmaceutics

General Pharmacology

Toxicology and Pharmaceutics Biochemistry

Genetics and Molecular Biology

Molecular Medicine

Latest Journal

Yaoxue Xuebao

Pharmacokinetics of PROTACs and their research progress in disease treatment

Proteolysis-targeting chimera (PROTAC) technology is a groundbreaking therapeutic approach with significant clinical potential for degrading disease-inducing proteins within targeted cells. However, challenges related to insufficient target selectivity raise concerns about PROTAC toxicity toward normal cells. To address this issue, researchers are modifying PROTACs using various approaches to enhance their target specificity. This review highlights innovative optically controlled PROTACs as anti-cancer therapies currently used in clinical practice and explores the challenges associated with

read more..

Development of analgesic drugs targeting Nav1.7: advances in clinical trials and discovery of selective inhibitors

Chronic pain is a widespread disorder affecting millions of people and is insufficiently addressed by current classes of analgesics due to significant long-term or high dosage side effects. A promising approach that was recently proposed involves the systemic inhibition of the voltage-gated sodium channel Nav1.7, capable of cancelling pain perception completely. Notwithstanding numerous attempts, currently no drugs have been approved for the inhibition of Nav1.7. The task is complicated by the difficulty of creating a selective drug for Nav1.7, and avoiding binding to the many human paralog

read more..

Exploration of the antioxidant role and mechanism of Astragalus membranaceus based on a glucose-induced Caenorhabditis elegans model

Astragali radix is a traditional medicinal herb with a long history and wide application. It is frequently used in prescriptions with other medicinal materials to replenish Qi. According to the classics of traditional Chinese medicine, Astragali radix is attributed with properties such as Qi replenishing and surface solidifying, sore healing and muscle generating, and inducing diuresis to reduce edema. Modern pharmacological studies have demonstrated that some extracts and active ingredients in Astragali radix function as antioxidants. The polysaccharides, saponins, and flavonoids in Astrag

read more..

Pharmacokinetics of wogonin-aloperine cocrystal in rats

Bexarotene (BEX), a specific retinoic acid X receptor (RXR) agonist granted by Food and Drug Administration (FDA) approval for the clinical treatment of T cell lymphoma, has now been found to exert pharmacological effects in the nervous system, with low bioavailability and poor cerebral distribution limiting its application in treatment on neurological disorders. Pharmaceutical co-crystal was a helpful method to improve the bioavailability and tissue distribution of active pharmaceutical ingredients (APIs). Here, 2bexarotene-ligustrazine (2BEX-LIG), a novel co-crystal system of BEX and ligu

read more..

Application progress of radiolabeling strategies in human mass balance studies

Human radiolabeled mass balance studies are an important component of the clinical pharmacology programs supporting the development of new investigational drugs. These studies allow for understanding of the absorption, distribution, metabolism, and excretion of the parent drug and metabolite(s) in the human body. Understanding the drug's disposition as well as metabolite profiling and abundance via mass balance studies can help inform the overall drug development program. A survey of the US Food and Drug Administration (FDA)‐approved new drug applications (NDAs) indicated that about 6

read more..